Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) saw a large decline in short interest in October. As of October 30th, there was short interest totaling 29,458 shares, a decline of 47.6% from the October 15th total of 56,196 shares. Based on an average daily volume of 7,414 shares, the short-interest ratio is presently 4.0 days.
Medexus Pharmaceuticals Stock Performance
MEDXF stock traded up $0.14 during trading on Tuesday, hitting $4.15. 22,050 shares of the stock traded hands, compared to its average volume of 12,974. Medexus Pharmaceuticals has a 1 year low of $1.80 and a 1 year high of $4.17. The firm’s 50 day moving average is $3.55 and its two-hundred day moving average is $3.07.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines for patients with underserved medical needs. Its activities span areas including hematology, oncology, rheumatology and allergy. In the United States, its marketed products include IXINITY, a recombinant factor IX treatment for hemophilia B; Gleolan, used to help surgeons visualize certain brain tumors; and Rasuvo, a methotrexate injection for inflammatory conditions. In Canada, Medexus markets products including Rupall, an antihistamine, and Metoject, a methotrexate product.
Further Reading
- Five stocks we like better than Medexus Pharmaceuticals
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
